卡比多巴预处理后早期18F-FDOPA PET/CT在胰岛素瘤诊断中的价值
本研究回顾性纳入24例组织学证实的胰岛素瘤患者(共25次术前检查),评估口服卡比多巴预处理后早期胰腺采集的18F-FDOPA PET/CT。结果显示原发灶检出率为84%,其中19%病灶仅早期采集可见,良性胰岛素瘤早期SUVmax显著高于延迟期,恶性者摄取更高;结论认为该方案在GLP1R显像不可及时是有价值的诊断选择。
要点
- 卡比多巴预处理后早期胰腺采集的18F-FDOPA PET/CT对胰岛素瘤原发灶检出率为84%。
- 19%的病灶仅在早期采集(注射后5分钟)中检出。
- 良性胰岛素瘤早期SUVmax显著高于延迟期,恶性者摄取显著更高。
核心结论
- 卡比多巴预处理联合早期胰腺采集的18F-FDOPA PET/CT在GLP1R显像不可及时是胰岛素瘤的有价值诊断选择。
研究设计与样本
- 回顾性纳入24例组织学证实的胰岛素瘤患者,共25次术前18F-FDOPA PET/CT检查。
- 所有检查均在口服卡比多巴200 mg(注射前1-2小时)预处理下进行。
- PET/CT协议包括注射后5分钟上腹部早期采集和20-30分钟后延迟全身采集。
- 以细胞学/组织病理学诊断胰岛素瘤为诊断金标准。
主要发现
- 25次检查中21次定位胰岛素瘤,原发灶检出率84%。
- 4个病灶(19%)仅在早期采集中检出。
- PET/CT时接受低血糖症状治疗与未治疗患者的假阴性肿瘤检出率分别为22%和12.5%。
- 良性胰岛素瘤早期SUVmax显著高于延迟期SUVmax。
- 与21个良性病灶相比,4个恶性胰岛素瘤的18F-FDOPA摄取显著更高。
关键数值与推荐
- 口服卡比多巴200 mg,注射前1-2小时给予。
- 早期采集为18F-FDOPA注射后5分钟,延迟全身采集在20-30分钟后开始。
- 原发灶检出率84%(21/25次检查)。
- 仅早期采集检出病灶占19%(4个)。
- 接受与未接受低血糖症状治疗患者的假阴性率分别为22%和12.5%。
临床怎么用
- 对疑似胰岛素瘤相关高胰岛素性低血糖患者,在GLP1R显像不可及时可考虑卡比多巴辅助18F-FDOPA PET/CT。
- 采集方案应包含注射后5分钟的上腹部早期采集,以避免遗漏仅早期显影的病灶。
- 判读时应结合早期与延迟期SUVmax,并注意病灶大小、空腹胰岛素和C肽水平与摄取的相关性。
局限性
- 回顾性研究设计。
- 样本量较小(24例患者、25次检查)。
- 恶性胰岛素瘤病灶数少(4个)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Data on the diagnostic value of 18F-FDOPA PET/CT in patients with insulinoma are limited and are focused on small patient populations explored using different PET/CT protocols and the inconsistent use of carbidopa premedication. The aim of this study was to improve the current knowledge about the diagnostic value of 18F-FDOPA PET/CT combined with oral carbidopa premedication and early pancreatic imaging for tumour localization in patients with insulinoma-related hyperinsulinaemic hypoglycaemia (HH). The relationships among 18F-FDOPA quantitative uptake parameters, insulin secretion and tumour pathological features were also investigated. METHODS: Of 34 patients with suspicion of insulinoma-related HH examined by dual time-point carbidopa-assisted 18F-FDOPA PET/CT, 24 with histologically proven insulinoma were retrospectively included. One patient underwent two PET/CT examinations for relapsing insulinoma after surgical excision. Thus, 25 preoperative 18F-FDOPA PET/CT studies were finally retained and analysed. All studies were performed under carbidopa premedication (200 mg orally, 1-2 h prior to tracer injection). The PET/CT acquisition protocol included an early acquisition (5 min after 18F-FDOPA injection) over the upper abdomen and a delayed whole-body acquisition starting 20-30 min later. The cytological and/or histopathological diagnosis of insulinoma was the diagnostic standard of truth. RESULTS: 18F-FDOPA PET/CT localized insulinoma in 21 of the 25 studies, leading to a primary lesion detection rate of 84%. Four lesions (19%) were detected only on early acquisitions. The false-negative tumour detection rates were, respectively, 22% and 12.5% in patients receiving and not receiving treatment for hypoglycaemic symptoms at the time of PET/CT. In benign insulinomas, the early maximum standardized uptake value (SUVmax) was significantly higher than the delayed SUVmax. Compared to the 21 benign lesions, four malignant insulinomas showed significantly higher 18F-FDOPA uptake. Lesion size, fasting-end insulin and C-peptide levels correlated with tumour 18F-FDOPA uptake, dopaminergic tumour volume and metabolic burden. CONCLUSION: The present study showed that 18F-FDOPA PET/CT combined with carbidopa premedication and early pancreatic acquisitions is a valuable diagnostic option in patients with insulinoma when GLP1R-based imaging is not available. The results also provide new insights into the relationships between tumour secretion and imaging phenotype in insulinomas.
引用
- Leroy-Freschini B, Amodru V, Addeo P, et al. Early 18F-FDOPA PET/CT imaging after carbidopa premedication as a valuable diagnostic option in patients with insulinoma. Eur J Nucl Med Mol Imaging. 2019. PMID: 30617961. doi:10.1007/s00259-018-4245-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。